Sathyamurthy I, Bahuleyan C G, Srinivas Arun, Gadkari Milind, Kumar Soumitra, Ratnaparkhi G, Mahurkar Uday
Department of Cardiology, Manipal Heart Institute, Bangalore, Karnataka, India.
Indian Heart J. 2011 May-Jun;63(3):234-6.
To analyze the efficacy and safety of indigenous Tenecteplase in Indian elderly STEMI patients in a clinical setting.
Post-licensure, observational, prescription event monitoring (PEM) study.
2162 patients received weight-adjusted Tenecteplase injection. The data for elderly (> 60 years) and non-elderly (< or = 60 years) was identified, segregated and compared. Out of 2162 patients, 805 were elderly patients and 1357 were non-elderly. Clinically successful thromolysis was seen in 83.98% of elderly and 86% of non-elderly group (p = 0.22). There was no significant difference in percentage of patients reporting bleeding, stroke, intracranial hemorrhage, myocardial reinfraction, ventricular tachyarrhythmia between the groups. Mortality was significantly (p = < 0.0001) more in elderly (6.21%) than non-elderly (2.06%) patients.
The indigenously developed Tenecteplase shows high efficacy and safety in its in-hospital use in Indian elderly patients with STEMI.
